Elite in Non-Alcoholic Fatty Liver Disease

Dr. Manal F. Abdelmalek

Hepatology
200 1st St Sw, 
Rochester, MN 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
27 Years of Experience
Elite in Non-Alcoholic Fatty Liver Disease
200 1st St Sw, 
Rochester, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Manal Abdelmalek is a Hepatologist in Rochester, Minnesota. Dr. Abdelmalek has been practicing medicine for over 27 years and is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. Her top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, Cirrhosis, Enlarged Liver, and Liver Transplant. Dr. Abdelmalek is currently accepting new patients.

Her clinical research consists of co-authoring 155 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 138 articles and participated in 13 clinical trials in the study of Non-Alcoholic Fatty Liver Disease.

Specialties
Hepatology
Licenses
Internal Medicine in NC
Hospital Affiliations
Mayo Clinic Hospital Rochester
Languages Spoken
English
Arabic
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

MAYO CLINIC
200 1st St Sw, Rochester, MN 55905

Additional Areas of Focus

Dr. Abdelmalek has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Recruiting
Publish Date: March 21, 2025
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Statins in Adult Patients With Non-Alcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Statins in Adult Patients With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Recruiting
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drug: Atorvastatin
Study Phase: Phase 2
Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD
Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Vitamin E
Study Phase: Phase 2
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
Enrollment Status: Active_not_recruiting
Publish Date: March 21, 2025
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
Clinical Study of the BreathID® LF System to Train the Algorithm for the ¹³C-Methacetin Breath Test (MBT) in Assessment of Portal Hypertension in Patients With Compensated Liver Cirrhosis
Clinical Study of the BreathID® LF System to Train the Algorithm for the ¹³C-Methacetin Breath Test (MBT) in Assessment of Portal Hypertension in Patients With Compensated Liver Cirrhosis
Enrollment Status: Completed
Publish Date: December 20, 2022
Intervention Type: Device
Study Phase: Not Applicable
Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance (MR) Biomarkers in Nonalcoholic Fatty Liver Disease (NAFLD)
Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance (MR) Biomarkers in Nonalcoholic Fatty Liver Disease (NAFLD)
Enrollment Status: Terminated
Publish Date: August 31, 2022
Intervention Type: Other, Drug
Study Drug: Intravenous fructose challenge
Study Phase: Phase 2
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
Enrollment Status: Completed
Publish Date: February 23, 2022
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 07, 2019
Intervention Type: Drug
Study Phase: Phase 2
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
Enrollment Status: Terminated
Publish Date: July 11, 2017
View 12 Less Clinical Trials

155 Total Publications

Author Correction: Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction.
Author Correction: Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction.
Journal: Nature communications
Published: May 06, 2025
Similar Doctors
Elite in Non-Alcoholic Fatty Liver Disease
Dr. Alina M. Allen
Hepatology
Elite in Non-Alcoholic Fatty Liver Disease
Dr. Alina M. Allen
Hepatology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 mi)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alina Allen is a Hepatologist in Rochester, Minnesota. Dr. Allen and is rated as a Distinguished provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. Her top areas of expertise are Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Ascites, Cirrhosis, and Liver Transplant. Dr. Allen is currently accepting new patients.

Elite in Non-Alcoholic Fatty Liver Disease
Dr. Harmeet Malhi
Hepatology
Elite in Non-Alcoholic Fatty Liver Disease
Dr. Harmeet Malhi
Hepatology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 mi)
507-284-2511
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Accepting New Patients

Harmeet Malhi is a Hepatologist in Rochester, Minnesota. Dr. Malhi and is rated as a Distinguished provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. Her top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, Hepatitis, Cirrhosis, and Liver Transplant. Dr. Malhi is currently accepting new patients.

Advanced in Non-Alcoholic Fatty Liver Disease
Dr. Patrick S. Kamath
Hepatology
Advanced in Non-Alcoholic Fatty Liver Disease
Dr. Patrick S. Kamath
Hepatology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 mi)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Kamath is a Hepatologist in Rochester, Minnesota. Dr. Kamath and is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Ascites, Liver Failure, Spontaneous Bacterial Peritonitis, Liver Transplant, and Endoscopy. Dr. Kamath is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Abdelmalek's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile